Study title: Double-blind parallel multisite study of the safety and efficacy of cetirizine 5mg QAM and 10mg QAM vs placebo in the treatment of patients with perennial allergic rhinitis. Summary of studies 89-N-0101 -0108, 89-N-0110, Volumes 1-2 of 2 submitted to NDA 19-835 16 Sep 1991
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Respiratory Tract Diseases [C08] | |||||
Brands: | |||||
MAH holders: | |||||
Assessment: | |||||
Active substance: CETIRIZINE | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: PAR-4 89CE16-0448 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |